LA JOLLA PHARMACEUTICAL SAYS ITS MARKETING AUTHORIZATION APPLICATION HAS BEEN ACCEPTED BY EUROPEAN MEDICINES AGENCY FOR RIQUENT

La Jolla Pharmaceutical announced that its Marketing Authorization Application has been accepted for review by the European Medicines Agency for potential approval to market Riquent, its drug candidate for lupus renal disease, in the European Union.
Streetinsider.com